Video

Dr. Roila on Aprepitant for the Prevention of Cisplatin-Induced Delayed Emesis

Fausto Roila, MD, chair, Medical Oncology Division, S. Maria Hospital, Terni, Italy, discusses an analysis of aprepitant for the prevention of cisplatin-induced delayed emesis.

Fausto Roila, MD, chair, Medical Oncology Division, S. Maria Hospital, Terni, Italy, discusses an analysis of aprepitant for the prevention of cisplatin-induced delayed emesis that was presented at the 2014 MASCC/ISOO International Symposium.

This analysis compared aprepitant, an NK1 receptor inhibitor, and dexamethasone to metoclopramide and dexamethasone for the prevention of delayed emesis. In a previous analysis, aprepitant demonstrated benefit on day 1 and day 2-5. However, the benefit experienced on day 2-5 with aprepitant may be a continuation of the initial benefit induced on day 1, Roila suggests.

In this analysis, the benefit was essentially the same on day 1 between patients receiving aprepitant plus dexamethasone and those receiving metoclopramide plus dexamethasone. On day 2-5, complete response rate was not significantly different: 80.3% in the aprepitant arm compared with 82.5% in the metoclopramide arm. Secondary endpoints were also similar, suggesting that neither therapy is superior.

<<<

View more from the 2014 MASCC/ISOO Symposium

Related Videos
Benjamin P. Levy, MD, with Kristie Kahl and Andrew Svonavec
Binod Dhakal, MD
Jill Corre, PharmD, PhD
Saad Z. Usmani, MD, MBA, FACP, FASCO
Ashraf Z. Badros, MBCHB
Thierry Andre, MD, professor, medical oncology, Sorbonne Université; head, Medical Oncology Department, Saint Antoine Hospital
Sanjay Popat, BSc, MBBS, FRCP, PhD, consultant medical oncologist, The Royal Marsden Hospital; professor, thoracic oncology, the Institute of Cancer Research
Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, co-leader, kidney cancer program, Dana-Farber Cancer Institute; Jerome and Nancy Kohlberg Chair, professor, medicine, Harvard Medical School
Angeles A. Secord, MD, MHSc, professor, obstetrics and gynecology, Duke Cancer Institute, discusses findings from the phase 2 PICCOLO trial (NCT05041257) investigating mirvetuximab soravtansine-gynx (Elahere) in patients with recurrent, platinum-sensitive ovarian cancer with high folate receptor alpha (FRα) expression.
Nancy U. Lin, MD, associate chief, Division of Breast Oncology, Susan F. Smith Center for Women’s Cancers, director, Metastatic Breast Cancer Program, director, Program for Patients with Breast Cancer Brain Metastases, Dana-Farber Cancer Institute; professor, medicine, Harvard Medical School